An SGLT2 Inhibitor, called empagliflozin (US brand name Jardiance), has shown promise as an alternative or supplement to G-CSF for treating neutropenia and neutrophil dysfunction in GSD1b. Data from an international questionnaire showed positive effects on all neutrophil dysfunction-related symptoms, including oral and urogenital mucosal lesions, recurrent infections, skin abscesses, inflammatory bowel disease, and anemia (Grunert, et all). Always discuss treatment options with your care team. Additional recommendations, developed by an expert panel of clinicians and researchers can be found HERE.
Publications on the use of empagliflozin in GSD1b are growing each year. For more published literature on its use in pediatric and adult patients, search “empagliflozin” in the GSD1b Published Literature link HERE.
Ask the Expert Webinar on the use of empagliflozin in GSD1b. Watch the webinar here.
Treating Neutropenia in Glycogen Storage Disease Type 1b Using Empagliflozin. Click to Watch Video
Read about Nina’s story to get treatment as told by her parents Lande and Marta: Click to Learn More
